Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Azeliragon

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cantex Pharma: Four Azeliragon Abstracts At ASCO 2024 Annual Meeting
    Cantex Pharma: Four Azeliragon Abstracts At ASCO 2024 Annual Meeting

    28 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-four-abstracts-to-be-presented-featuring-azeliragon-at-2024-asco-annual-meeting-302155456.html

    PR NEWSWIRE
    28 May 2024
    Share Share
    CANTEX Gets FDA Orphan Drug For Azeliragon In Pancreatic Cancer
    CANTEX Gets FDA Orphan Drug For Azeliragon In Pancreatic Cancer

    20 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-receives-fda-orphan-drug-designation-for-azeliragon-for-the-treatment-of-pancreatic-cancer-302150254.html

    PR NEWSWIRE
    20 May 2024
    Share Share
    Cantex & Michigan Announce Initiation Of Phase 3 Trial To Evaluate Azeliragon
    Cantex & Michigan Announce Initiation Of Phase 3 Trial To Evaluate Azeliragon

    27 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cantex-and-michigan-medicine-announce-initiation-of-a-randomized-double-blind-placebo-controlled-multicenter-phase-3-pivotal-clinical-trial-to-evaluate-the-safety-and-efficacy-of-azeliragon-in-the-treatment-of-patients-hospita-301939862.html

    PR NEWSWIRE
    27 Sep 2023
    Share Share
    Cantex and Allegheny Health Announce Initiation of a Phase 1/2 of Azeliragon
    Cantex and Allegheny Health Announce Initiation of a Phase 1/2 of Azeliragon

    26 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cantex-and-allegheny-health-network-announce-initiation-of-a-phase-12-study-of-azeliragon-in-patients-refractory-to-first-line-treatment-of-metastatic-pancreatic-cancer-301936563.html

    PR NEWSWIRE
    26 Sep 2023
    Share Share
    Cantex & Lenox Hill Hospital Announce Initiation of Phase 2 Study of Azeliragon
    Cantex & Lenox Hill Hospital Announce Initiation of Phase 2 Study of Azeliragon

    18 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-and-lenox-hill-hospital-announce-initiation-of-a-phase-2-study-of-rage-inhibitor-azeliragon-as-a-front-line-treatment-for-unmethylated-glioblastoma-301930043.html

    PR NEWSWIRE
    18 Sep 2023
    Share Share
    Cantex Announces Initiation of Invg-Initiated Ph2 Trial Investigating Azeliragon
    Cantex Announces Initiation of Invg-Initiated Ph2 Trial Investigating Azeliragon

    28 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-initiation-of-an-investigator-initiated-phase-2-clinical-trial-investigating-azeliragon-combined-with-stereotactic-radiosurgery-for-the-treatment-of-brain-metastases-301911475.html

    PR NEWSWIRE
    28 Aug 2023
    Share Share